SI-613 Study for Knee Osteoarthritis

NCT ID: NCT03209362

Last Updated: 2021-11-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-19

Study Completion Date

2018-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the efficacy and safety of intra-articular injections of SI-613 compared with placebo for knee OA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Knee Osteoarthritis Intra-articular injection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SI-613

Group Type EXPERIMENTAL

SI-613

Intervention Type COMBINATION_PRODUCT

SI-613 will be repeated intra-articularly administered.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type COMBINATION_PRODUCT

Placebo will be repeated intra-articularly administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SI-613

SI-613 will be repeated intra-articularly administered.

Intervention Type COMBINATION_PRODUCT

Placebo

Placebo will be repeated intra-articularly administered.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provides their written informed consent.
* Has a diagnosis at the time of screening of OA of the knee according to American College of Rheumatology (ACR) criteria
* Is willing to switch to using acetaminophen as a rescue medication

Exclusion Criteria

* Has a body mass index (BMI) greater than or equal to 40 kg/m2 at screening.
* Secondary OA
* Is a female subject who is pregnant or lactating.
* Is currently hospitalized or has a planned hospitalization during the life of the study.
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chiltern International Inc.

INDUSTRY

Sponsor Role collaborator

Seikagaku Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson Orthopaedic Institute

Tucson, Arizona, United States

Site Status

MM Medical Center, Inc.

Miami, Florida, United States

Site Status

Quality Research and Medical Center, LLC

Miami, Florida, United States

Site Status

Heartland Research Associates, LLC

Newton, Kansas, United States

Site Status

Central Kentucky Research Associates

Lexington, Kentucky, United States

Site Status

Sundance Clinical Research, LLC

St Louis, Missouri, United States

Site Status

Rochester Clinical Research

Rochester, New York, United States

Site Status

Upstate Clinical Research Associates, LLC

Williamsville, New York, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

613 /1121

Identifier Type: -

Identifier Source: org_study_id